How Generalizable are Randomized Controlled trials (RCTs) in Staphylococcus aureus Bacteremia? A Description of the Mortality Gap Between RCTs and Observational Studies
Loading...
Files
Date
Authors
Bai, Anthony
Lo, Carson K. L.
Komorowski, Adam
Suresh, Mallika
Guo, Kevin
Garg, Akhil
Tandon, Pranav
Senecal, Julien
Del Corpo, Olivier
Stefanova, Isabella
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Abstract
In Staphylococcus aureus bacteremia, mortality rates in randomized controlled trials (RCTs) are consistently lower than observational studies. Stringent eligibility criteria and omission of early deaths in RCTs contribute to this mortality gap. Clinicians should acknowledge the possibility of a lower treatment effect when applying RCT results to bedside care.
Description
This is an Accepted Manuscript of an article published by Oxford University Press in the journal Clinical Infectious Diseases on March 4, 2022 available online at https://doi.org/10.1093/cid/ciac177
Keywords
Staphylococcus aureus, Bacteremia, Mortality, Trials
Citation
Anthony D Bai, MD, Carson K L Lo, MD, Adam S Komorowski, MD, Mallika Suresh, HBSc, Kevin Guo, Akhil Garg, MDCM, Pranav Tandon, MSc, Julien Senecal, BSc, Olivier Del Corpo, MDCM MSc, Isabella Stefanova, BSc, Clare Fogarty, MDCM, Guillaume Butler-Laporte, MD, Emily G McDonald, MD MSc, Matthew P Cheng, MDCM, Andrew M Morris, MD SM, Mark Loeb, MD MSc, Todd C Lee, MD MPH, How generalizable are randomized controlled trials (RCTs) in Staphylococcus aureus bacteremia? A description of the mortality gap between RCTs and observational studies, Clinical Infectious Diseases, 2022;, ciac177, https://doi.org/10.1093/cid/ciac177